Metformax Combi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metformax Combi, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to control blood glucose levels.

GNH USA supplies Metformax Combi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformax Combi is used in the treatment of type 2 diabetes mellitus and related hyperglycaemic conditions. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels. - Adults with inadequate glycaemic control on metformin alone: provides additional glucose‑lowering effect. - Patients requiring combination therapy to simplify regimen: combines two mechanisms in a single tablet for improved adherence.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headache. - Upper respiratory tract infection: cold‑like symptoms. - Hypoglycaemia (when used with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Pancreatitis: inflammation of the pancreas. - Hepatic failure: impaired liver function. - Severe hypoglycaemia: especially with concomitant insulin. - Anaphylactic reactions: rare allergic responses.

Metformax Combi should be used with caution in specific clinical situations. - Renal function: assess eGFR before initiating and monitor periodically. - Hepatic impairment: avoid or use with close monitoring. - Risk of lactic acidosis: contraindicated in conditions predisposing to hypoxia. - Pregnancy: safety not established; discuss risks with a healthcare provider. - Drug interactions: review all concomitant medications for potential interactions. - Store at ambient temperature: keep below 25°C, in the original pack, protect from moisture.

Metformax Combi may interact with several medicines; monitoring is essential. Major Interactions (Avoid): - Concomitant insulin or sulfonylureas: increased risk of hypoglycaemia. - Renal toxic agents (e.g., iodinated contrast): may worsen renal function and raise metformin levels. - Cimetidine: can increase metformin plasma concentrations. Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycaemia. - Diuretics: can affect renal clearance of metformin. - Alcohol: may heighten the risk of lactic acidosis.